Send to

Choose Destination
J Rheumatol. 1995 Sep;22(9):1660-2.

A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica.

Author information

Department of Internal Medicine, Deaconess House Saint Luke's Foundation's Hospital, Hellerup, Denmark.



The aim of the study was to establish the antiinflammatory equipotency between prednisolone and deflazacort.


Thirty patients with newly diagnosed polymyalgia rheumatica (PMR) were treated double blind with either prednisolone or deflazacort in a 12-month study. The initial daily dose was 20 mg prednisolone or 24 mg deflazacort.


The clinical control of muscle pain was significantly inferior in the deflazacort group from 6 weeks to 3 months. Otherwise there was no difference in the clinical and biochemical variables. The ratio between antiinflammatory equipotent doses of deflazacort and prednisolone (mg:mg) stabilized at about 1.55 for the daily doses and about 1.40 for the cumulative doses.


In PMR the antiinflammatory equipotency (mg to mg) between deflazacort and prednisolone was close to 1.40 (7:5 mg). Twenty mg prednisolone/day was fully sufficient to suppress symptoms in 94% of the patients.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center